Pharmacotherapy of COVID-19: in vitro and in vivo application of remdesivir

Authors

  • Mariana de Almeida Rosa Rezende Universidade Federal de Juiz de Fora, UFJF - Campus Avançado Governador Valadares, Instituto de Ciências da Vida. Rua São Paulo, 745, Centro 35010180 - Governador Valadares, MG - Brasil http://orcid.org/0000-0002-0237-2946
  • Alice Ferreira Cordeiro Universidade Federal de Juiz de Fora, UFJF - Campus Avançado Governador Valadares, Instituto de Ciências da Vida. Rua São Paulo, 745, Centro 35010180 - Governador Valadares, MG - Brasil
  • Andrey Paradela de Sousa Universidade Federal de Juiz de Fora, UFJF - Campus Avançado Governador Valadares, Instituto de Ciências da Vida. Rua São Paulo, 745, Centro 35010180 - Governador Valadares, MG - Brasil
  • Isadora Valério da Silveira Universidade Federal de Juiz de Fora, UFJF - Campus Avançado Governador Valadares, Instituto de Ciências da Vida. Rua São Paulo, 745, Centro 35010180 - Governador Valadares, MG - Brasil

DOI:

https://doi.org/10.14450/2318-9312.v34.e1.a2022.pp45-57

Keywords:

pharmacotherapy, COVID-19, antiviral.

Abstract

The coronavirus (SARS-CoV-2) is a pathogen that causes severe acute respiratory syndrome in humans (COVID-19). Its outbreak has engulfed the world suddenly, leading to a global pandemic crisis. This review article was designed to evaluate the existing evidence and experience related to an already-approved pharmacologic agent called remdesivir. PubMed, Scopus, Web of Science, and SCIELO databases were used to search for word-combinations, such as “COVID-19 AND Remdesivir” or “SARS-CoV-2 AND
Remdesivir”. Four reviewers independently searched results and abstracted data from selected studies up to March 21. Remdesivir has been shown to inhibit SARS-CoV-2, in vitro and in vivo, with therapeutic potential in treating patients hospitalized with COVID-19. However, it has been associated with the
development of adverse effects.

Author Biographies

Mariana de Almeida Rosa Rezende, Universidade Federal de Juiz de Fora, UFJF - Campus Avançado Governador Valadares, Instituto de Ciências da Vida. Rua São Paulo, 745, Centro 35010180 - Governador Valadares, MG - Brasil

Farmacêutica, professora de Farmacologia do Departamento de Ciências Básicas da Vida - Instituto de Ciências da Vida. UFJF/GV

Isadora Valério da Silveira, Universidade Federal de Juiz de Fora, UFJF - Campus Avançado Governador Valadares, Instituto de Ciências da Vida. Rua São Paulo, 745, Centro 35010180 - Governador Valadares, MG - Brasil

FARMACOTERAPIA DA COVID-19: APLICAÇÃO DO REMDESIVIR IN VITRO E IN VIVO

Downloads

Published

2022-04-08

How to Cite

Rezende, M. de A. R., Cordeiro, A. F., Sousa, A. P. de, & Silveira, I. V. da. (2022). Pharmacotherapy of COVID-19: in vitro and in vivo application of remdesivir. Infarma - Pharmaceutical Sciences, 34(1), 45–57. https://doi.org/10.14450/2318-9312.v34.e1.a2022.pp45-57

Issue

Vol. 34 No. 1 (2022)

Section

Review Article

License

Authors who publish in this journal agree to the following terms:

 

  1. Authors retain the copyright and grant the journal the right of first publication, with the work simultaneously licensed under the Licença Creative Commons Attribution which allows the sharing of work with acknowledgment of authorship and initial publication in this journal.
  2. Authors are authorized to take additional contracts separately, for non-exclusive distribution of the version of the work published in this journal (e.g. publish in institutional repository or as a book chapter), with acknowledgment of authorship and initial publication in this journal.
  3. Authors are allowed and encouraged to publish and distribute their work online (e.g. in institutional repositories or on their personal page) at any point before or during the editorial process, as this can generate productive changes as well as increase the impact and Citation of published work (See O Efeito do Acesso Livre ).